Chemomab Therapeutics (CMMB) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free CMMB Stock Alerts $0.82 -0.04 (-4.65%) (As of 05/21/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17, 2024 | globenewswire.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 15, 2024 | americanbankingnews.comChemomab Therapeutics (NASDAQ:CMMB) Now Covered by Maxim GroupMay 14, 2024 | msn.comMaxim Group Initiates Coverage of Chemomab Therapeutics - Depositary Receipt () (CMMB) with Buy RecommendationMay 13, 2024 | americanbankingnews.comShort Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Declines By 25.1%May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)May 9, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleMay 2, 2024 | globenewswire.comChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceApril 24, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 18, 2024 | globenewswire.comChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisApril 8, 2024 | finance.yahoo.comChemomab Therapeutics Ltd. (CMMB)April 2, 2024 | globenewswire.comChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024March 25, 2024 | globenewswire.comChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisMarch 7, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023March 7, 2024 | finanznachrichten.deChemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 7, 2024 | finance.yahoo.comChemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 5, 2024 | prnewswire.comChemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceFebruary 20, 2024 | msn.comBiotech Shares Massively Bid Up Before Opening BellFebruary 20, 2024 | finance.yahoo.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | prnewswire.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 14, 2024 | finance.yahoo.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | prnewswire.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 5, 2024 | finance.yahoo.comChemomab Therapeutics to Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comChemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisJanuary 6, 2024 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comChemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024December 29, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Insider TradesDecember 21, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, PredictionsDecember 6, 2023 | msn.comHere's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock NowNovember 16, 2023 | finance.yahoo.comChemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNovember 15, 2023 | markets.businessinsider.comUS Stocks Gain; Producer Prices Fall In OctoberNovember 15, 2023 | markets.businessinsider.comChemomab Reports Fast Track Designation For CM-101 - Quick FactsNovember 15, 2023 | msn.comWhy is Liver Disease Focused Chemomab Stock Trading Higher Today?November 15, 2023 | finance.yahoo.comChemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNovember 13, 2023 | finance.yahoo.comChemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023November 9, 2023 | finanznachrichten.deChemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 9, 2023 | msn.comChemomab Therapeutics GAAP EPS of $0.017November 9, 2023 | finance.yahoo.comChemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | msn.comChemomab Therapeutics receives Nasdaq notice regarding minimum bid price requirementOctober 30, 2023 | finance.yahoo.comChemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business UpdateOctober 16, 2023 | seekingalpha.comChemomab Therapeutics files for $200M mixed shelfOctober 8, 2023 | msn.comRoth MKM Initiates Coverage of Chemomab Therapeutics Ltd - ADR (CMMB) with Buy RecommendationOctober 8, 2023 | msn.comRoth MKM Initiates Coverage of Chemomab Therapeutics Ltd - ADR (CMMB) with Buy RecommendationSeptember 28, 2023 | finance.yahoo.comChemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities ConferenceAugust 29, 2023 | finance.yahoo.comChemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 14, 2023 | finanznachrichten.deChemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateAugust 14, 2023 | finance.yahoo.comChemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateJuly 6, 2023 | msn.comChemomab Therapeutics Ltd - ADR (CMMB) Price Target Increased by 70.45% to 25.50June 28, 2023 | finance.yahoo.comChemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. CMMB Media Mentions By Week CMMB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMMB News Sentiment▼0.000.44▲Average Medical News Sentiment CMMB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMMB Articles This Week▼21▲CMMB Articles Average Week Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MTEM News Today ATHE News Today NCNA News Today GRTX News Today UPC News Today ADXN News Today AEZS News Today GHSI News Today MBRX News Today MIRA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMMB) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceWrite this ticker symbol down…StocksToTradeFamous trader issues shocking June 12th warningTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
